National Institutes of Health (NIH)
Bethesda
MD
United States
224 articles with National Institutes of Health (NIH)
-
Albert Einstein College of Medicine Awarded $5 Million for Research on Intellectual and Developmental Disabilities
9/15/2021
Albert Einstein College of Medicine has received a five-year, $5 million grant from the National Institutes of Health to support the Rose F. Kennedy Intellectual and Developmental Disabilities Research Center, which has been at the forefront of research on normal and abnormal brain development for more than 50 years.
-
There were a fair number of clinical trial announcements last week. Here’s a look.
-
Heading into the Labor Day weekend in the U.S., there’s still plenty of COVID-19 news. Here’s a look.
-
A new study on COVID-19 behavior has found that patients affected by the virus might have died due to a buildup of coronavirus directly in the lungs and not because of a secondary infection.
-
NIH Backs Synchron Brain Computer Interface with $10M Grant to Launch First U.S. Clinical Trial
8/26/2021
NIH Backs Synchron Brain Computer Interface with $10M Grant to Launch First U.S. Clinical Trial
-
Excision Announces NIH Martin Delaney Grant Awarded to Temple University to Support “CRISPR for Cure” for HIV
8/26/2021
Excision BioTherapeutics Inc announced that the Temple University team collaborating with Excision on a project, CRISPR for Cure, has received a Martin Delaney Grant from the National Institutes of Health of $4.8 million on an annual basis for the next five years as a part of approximately $53 million annual funding from the NIH to find a cure for HIV.
-
Tabula Rasa and Hesperos Receive $1.9M National Institutes of Health Award for Research Focused on Preventable Drug-Induced Alzheimer's Disease
8/25/2021
Tabula Rasa HealthCare, Inc. and Hesperos Inc., pioneers of Human-on-a-Chip ® in vitro systems, have been awarded $1.9 million in funding from the National Institutes of Health (NIH) to investigate drug-induced dementia and develop new models that will drive Alzheimer's research.
-
Seattle Co Develops Rapid Fingerprinting For COVID-19 Variants
8/24/2021
ID Genomics, a Seattle-based company, has invented a dipstick-based, rapid test for simultaneous identification of a large number of genetic variants of SARS-CoV-2 and has just received a National Institutes of Health grant to expedite bringing this test to market.
-
President Biden is expected to be briefed on the lab leak theory conducted over the last 90 days. Very few expect solid results, although this might provide direction for more lines of inquiry.
-
Relief Reports that its U.S. Collaboration Partner has Announced a Positive Safety Report for ZYESAMI(TM) (aviptadil) in NIH Sponsored ACTIV-3 Study in Patients with Life-Threatening COVID-19
8/19/2021
RELIEF THERAPEUTICS Holding SA reported that the parent company of its U.S. collaboration partner, NRx Pharmaceuticals, Inc., provided a safety update on ZYESAMI which is being tested in the ACTIV-3 Critical Care Phase 3 study sponsored by the National Institutes of Health.
-
Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study
8/11/2021
Second Sight Medical Products, Inc. announces that the Company received a grant supplement from the National Institutes of Health to fund a qualitative study to gather critical insights into how profoundly blind people weigh the risks and benefits of visual neuroprostheses.
-
Feinstein Institutes receives $2.9M NIH grant for IVF genetic risk factors studies
8/2/2021
Genetic testing and selection of embryos generated from in vitro fertilization have given rise to the controversial “designer baby” debate.
-
Rep. Michael McCaul issued a third installment today into the origins of the COVID-19 virus and blames the pandemic on a leak from the Wuhan Institute of Virology in China.
-
Achieve Life Sciences Awarded Grant from the National Institutes of Health (NIH) for the Evaluation of Cytisinicline in Cessation of Nicotine E-cigarette Use
7/22/2021
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that it has been awarded a grant from the National Institute on Drug Abuse of the National Institutes of Health to evaluate the use of cytisinicline as a treatment for cessation of nicotine e-cigarette use.
-
COVID-19: Vaccines vs. Delta Variant, CDC Predicts Rising Death Toll in Unvaccinated and More
7/22/2021
As COVID-19 begins yet another surge across the U.S., there is some promising news about the effectiveness of vaccines. Here’s a look at some top COVID-19 stories. -
The device is at the core of the BRAVO trial, which evaluates signals to control complex devices for motor and speech in adults who have been severely affected by neurological disorders.
-
Ivermectin has become a contentious issue as to whether it effectively prevents and treats COVID-19. Several studies suggest it is effective, while others have indicated it is not.
-
Continuing studies and news about COVID-19 around the world keeps coming in. Here’s a look.
-
Amydis Receives $3 Million NIH Commercialization Readiness Pilot Grant Award for Novel Amyloid Beta Retinal Tracer in Cerebral Amyloid Angiopathy
6/28/2021
Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye, announced an award of a $3 million grant from the National Institute of Aging at National Institutes of Health.
-
Last summer, claims that the deadly SARS-CoV-2 virus emerged from a virology lab in Wuhan were generally dismissed by the scientific community as right-wing conspiracy theories. A year later, the theory isn’t sounding so far-fetched.